In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Impact of Arg16Gly and Gln27Glu polymorphism ADRB2 gene on cardiovascular events in patients with heart failure

Session Poster session 1 Saturday 08:30 -17:30

Speaker Associate Professor Elena Khazova

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P248

Authors : E Khazova (Kazan,RU), OV Bulashova (Kazan,RU), VM Gazizianova (Kazan,RU), MI Malkova (Kazan,RU), OA Kravtsova (Kazan,RU)


E Khazova1 , OV Bulashova1 , VM Gazizianova1 , MI Malkova1 , OA Kravtsova1 , 1Kazan State Medical University - Kazan - Russian Federation ,

European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 51

Introduction: There is a wide evidence of the gene polymorphism influence on Arg16Gly and Gln27Glu polymorphism of ADRB2 gene has been demonstrated to be contribute to cardiovascular events. The results are different and depend on social, demographic and other factors.

Aim: To study if ADRB2 gene polymorphism Arg16Gly and Gln27Glu are correlated with heart failure.

Methods: We enrolled 151 HF patients (age 64,6 ± 10,4 and left ventricular ejection fraction 53,8 ± 11,4%) and analyzed 1 year fatal and non-fatal cardiovascular events in association with Arg16Gly and Gln27Glu polymorphism ADRB2.

Results: Our results are statistically significant (p < 0,05) after comparing heart failure and non-cardiovascular diseases group with the frequency of occurrence genotypes Arg16Gly and Gln27Glu ADRD2. They show that subjects carrying the Glu27 of ADRB2 are more represented in HF patients (p = 0,04). Mortality was 9,5% and was highest in the Arg16Arg (42%,p = 0,03) and Glu27Gln (56%,p = 0,03) genotypes. Fatal myocardial infarction was associated with Glu27Gln (60%, p = 0,035) and non-fatal cardiovascular events (myocardial infarction, stroke, HF decompensation) - with the Arg16Arg polymorphism.

Conclusion: The Glu27Gln genotype ADRB2 more characterized HF patients than subjects without cardiovascular diseases (p = 0,04). Myocardial infarction and stroke are frequent in HF patients with Arg16Arg and Glu27Gln polymorphism ADRB2, however, non-fatal- Arg16Arg (p = 0,04).

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are